Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM’ pipeline disease-modifying therapies for Parkinson’s disease.
November 7, 2024
All about the disease